Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone

Abstract

Scl-AbI treatment does not prevent the detrimental effects of DEX on linear growth, but the antibody does increase both cortical and trabecular bone and improves bone mechanical properties in DEX-treated mice.